Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of CAN016 in advanced HER2-expressing or HER2-mutant solid tumors
CTR20262092Phase 2Active
- Sponsor
- Conway Biotech
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CAN016 in Nonhematologic neoplasms, sponsored by Conway Biotech. Started Jun 2026; status: active.
02
Drugs
CAN016
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20262092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262092.